Advanced MRI in the management of adult gliomas

British Journal of Neurosurgery

Volumn 21, Issue 6, 2007, Pages 550-561

  Jenkinson, M D ^a,c   Plessis, D G Du ^a   Walker, C ^a,b   Smith, T S ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b CLATTERBRIDGE HOSPITAL   (United Kingdom)

^c Clinical Science Centre   (United Kingdom)

Author keywords

Glioma; Management; MRI

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; CARBOPLATIN; CARMUSTINE; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW;

BRAIN NEOPLASMS; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MONITORING, INTRAOPERATIVE; NEUROSURGICAL PROCEDURES;

EID: 37049025568     PISSN: 02688697     EISSN: 1360046X     Source Type: Journal    
DOI: 10.1080/02688690701642020     Document Type: Review

References (65)

1. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90(19):1473-9.
2. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
3. Walker C, Haylock B, Husband D, et al. Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors. Neurology 2006;66:1661-7.
4. Aghi M, Gaviani P, Henson JW, et al. Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin Cancer Res 2005;11:8600-5.
5. Jenkinson MD, du Plessis DG, Smith TS, et al. Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 2006;129:1884-91.
6. Megyesi JF, Kachur E, Lee DH, et al. Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 2004;10:4303-6.
7. Mueller W, Hartmann C, Hoffmann A, et al. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 2002;161:313-19.
8. Mandonnet E, Delattre JY, Tanguy ML, et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol 2003;53:524-8.
9. Pallud J, Mandonnet E, Duffau H, et al. Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas. Ann Neurol 2006;60:380-3.
10. Tofts PS, Benton CE, Weil RS, et al. Quantitative analysis of whole-tumor Gd enhancement histograms predicts malignant transformation in low-grade gliomas. J Magn Reson Imaging 2007;25:208-14.
11. Macdonald DR, Cascino TL, Schold SC, Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80.
12. Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103:802-9.
13. Byrne TN. Response of low-grade oligodendroglial tumors to temozolomide. J Neurooncol 2004;70:279-80.
14. Preul MC, Caramanos Z, Leblanc R, Villemure JG, Arnold DL. Using pattern analysis of in vivo proton MRSI data to improve the diagnosis and surgical management of patients with brain tumors. NMR Biomed 1998;11(4-5):192-200.
15. Nelson SJ, Graves E, Pirzkall A, et al. In vivo molecular imaging for planning radiation therapy of gliomas: an application of 1H MRSI. J Magn Reson Imaging 2002;16:464-76.
16. Rabinov JD, Lee PL, Barker FG, et al. In vivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects: initial experience. Radiology 2002;225:871-9.
17. Schlemmer HP, Bachert P, Henze M, et al. Differentiation of radiation necrosis from tumor progression using proton magnetic resonance spectroscopy. Neuroradiology 2002;44(3):216-22.
18. Isobe T, Matsumura A, Anno I, et al. Quantification of cerebral metabolites in glioma patients with proton MR spectroscopy using T2 relaxation time correction. Magn Reson Imaging 2002;20:343-9.
19. Barbarella G, Ricci R, Pirini G, et al. In vivo single voxel 1H MRS of glial brain tumors: correlation with tissue histology and in vitro MRS. Int J Oncol 1998;12:461-8.
20. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24:1989-98.
21. Li X, Lu Y, Pirzkall A, et al. Analysis of the spatial characteristics of metabolic abnormalities in newly diagnosed glioma patients. J Magn Reson Imaging 2002;16:229-37.
22. Howe FA, Barton SJ, Cudlip SA, et al. Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med 2003;49:223-32.
23. Castillo M, Smith JK, Kwock L. Correlation of myo-inositol levels and grading of cerebral astrocytomas. AJNR Am J Neuroradiol 2000;21:1645-9.
24. Kuesel AC, Sutherland GR, Halliday W, Smith IC. 1H MRS of high grade astrocytomas: mobile lipid accumulation in necrotic tissue. NMR Biomed 1994;7(3):149-55.
25. Barba I, Cabanas ME, Arus C. The relationship between nuclear magnetic resonance-visible lipids, lipid droplets, and cell proliferation in cultured C6 cells. Cancer Res 1999;59:1861-8.
26. Walecki J, Tarasow E, Kubas B, et al. Hydrogen-1 MR spectroscopy of the peritumoral zone in patients with cerebral glioma: assessment of the value of the method. Acad Radiol 2003;10:145-53.
27. Rijpkema M, Schuuring J, Van Der Meulen Y, et al. Characterization of oligodendrogliomas using short echo time 1H MR spectroscopic imaging. NMR Biomed 2003;16:12-18.
28. Jenkinson MD, Smith TS, Joyce K, et al. MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes. Neurology 2005;64:2085-9.
29. Balmaceda C, Critchell D, Mao X, et al. Multisection 1H magnetic resonance spectroscopic imaging assessment of glioma response to chemotherapy. J Neurooncol 2006;76:185-91.
30. Laprie A, Pirzkall A, Haas-Kogan DA, et al. Longitudinal multivoxel MR spectroscopy study of pediatric diffuse brain-stem gliomas treated with radiotherapy. Int J Radiat Oncol Biol Phys 2005;62:20-31.
31. Tedeschi G, Lundbom N, Raman R, et al. Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. J Neurosurg 1997;87:516-24.
32. Cha S, Tihan T, Crawford F, et al. Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2005;26:266-73.
33. Jenkinson MD, Smith TS, Joyce KA, et al. Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. Neuroradiology 2006;48(10):703-13.
34. Cha S, Knopp EA, Johnson G, et al. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echoplanar perfusion MR imaging. Radiology 2002;223:11-29.
35. Law M, Oh S, Babb JS, et al. Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging - prediction of patient clinical response. Radiology 2006;238:658-67.
36. Maia AC, Jr, Malheiros SM, da Rocha AJ, et al. MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol 2005;26:777-83.
37. Sugahara T, Korogi Y, Kochi M, et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 1998;171:1479-86.
38. Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas. AJNR Am J Neuroradiol 2004;25:214-21.
39. Roberts HC, Roberts TP, Bollen AW, et al. Correlation of microvascular permeability derived from dynamic contrast-enhanced MR imaging with histologic grade and tumor labeling index: a study in human brain tumors. Acad Radiol 2001;8(5):384-91.
40. Xu M, See SJ, Ng WH, et al. Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors. Neurosurgery 2005;56:919-26; discussion 919-26.
41. Akella NS, Twieg DB, Mikkelsen T, et al. Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: quality and analysis results of a phase I trial. J Magn Reson Imaging 2004;20:913-22.
42. Cha S, Knopp EA, Johnson G, et al. Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. AJNR Am J Neuroradiol 2000;21:881-90.
43. Jager HR, Waldman AD, Benton C, Fox N, Rees J. Differential chemosensitivity of tumor components in a malignant oligodendroglioma: assessment with diffusion-weighted, perfusion-weighted, and serial volumetric MR imaging. AJNR Am J Neuroradiol 2005;26:274-8.
44. Leimgruber A, Ostermann S, Yeon EJ, et al. Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial. Int J Radiat Oncol Biol Phys 2006;64:869-75.
45. Moffat BA, Chen M, Kariaapper MS, et al. Inhibition of vascular endothelial growth factor (VEGF) - a causes a paradoxical increase in tumor blood flow and up-regulation of VEGF-D. Clin Cancer Res 2006;12:1525-32.
46. Jackson A, Kassner A, Zhu XP, Li KL. Reproducibility of T2* blood volume and vascular tortuosity maps in cerebral gliomas. J Magn Reson Imaging 2001;14:510-16.
47. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95.
48. Mills SJ, Patankar TA, Haroon HA, et al. Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? AJNR Am J Neuroradiol 2006;27:853-8.
49. Kono K, Inoue Y, Nakayama K, et al. The role of diffusionweighted imaging in patients with brain tumors. AJNR Am J Neuroradiol 2001;22:1081-8.
50. Fan GG, Deng QL, Wu ZH, Guo QY. Usefulness of diffusion/perfusion- weighted MRI in patients with non-enhancing supratentorial brain gliomas: a valuable tool to predict tumour grading? Br J Radiol 2006;79(944):652-8.
51. Tozer DJ, Jager HR, Danchaivijitr N, et al. Apparent diffusion coefficient histograms may predict low-grade glioma subtype. NMR Biomed 2006;20(1):49-57.
52. Sugahara T, Korogi Y, Kochi M, et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 1999;9:53-60.
53. Beppu T, Inoue T, Shibata Y, et al. Fractional anisotropy value by diffusion tensor magnetic resonance imaging as a predictor of cell density and proliferation activity of glioblastomas. Surg Neurol 2005;63:56-61; discussion 61.
54. Price SJ, Jena R, Burnet NG, et al. Improved delineation of glioma margins and regions of infiltration with the use of diffusion tensor imaging: an image-guided biopsy study. AJNR Am J Neuroradiol 2006;27:1969-74.
55. Stadlbauer A, Ganslandt O, Buslei R, et al. Gliomas: histopathologic evaluation of changes in directionality and magnitude of water diffusion at diffusion-tensor MR imaging. Radiology 2006;240:803-10.
56. Jenkinson MD, Smith TS, Brodbelt AR, et al. Apparent diffusion coefficients in oligodendroglial tumours characterised by genotype. J Magn Reson Imaging 2007 (in press).
57. Chenevert TL, Stegman LD, Taylor JM, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000;92(24):2029-36.
58. Tomura N, Narita K, Izumi J, et al. Diffusion changes in a tumor and peritumoral tissue after stereotactic irradiation for brain tumors: possible prediction of treatment response. J Comput Assist Tomogr 2006;30:496-500.
59. Hamstra DA, Chenevert TL, Moffat BA, et al. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci USA 2005;102:16759-64.
60. Vlieger EJ, Majoie CB, Leenstra S, Den Heeten GJ. Functional magnetic resonance imaging for neurosurgical planning in neurooncology. Eur Radiol 2004;14:1143-53.
61. Albayrak B, Samdani AF, Black PM. Intra-operative magnetic resonance imaging in neurosurgery. Acta Neurochir (Wien) 2004;146:543-56; discussion 557.
62. Berger MS, Rostomily RC. Low grade gliomas: functional mapping resection strategies, extent of resection, and outcome. J Neurooncol 1997;34:85-101.
63. Vuorinen V, Hinkka S, Farkkila M, Jaaskelainen J. Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir (Wien) 2003;145:5-10.
64. Nimsky C, Fujita A, Ganslandt O, Von Keller B, Fahlbusch R. Volumetric assessment of glioma removal by intraoperative high-field magnetic resonance imaging. Neurosurgery 2004;55:358-370.
65. Hirschberg H, Samset E, Hol PK, Tillung T, Lote K. Impact of intraoperative MRI on the surgical results for high-grade gliomas. Minim Invasive Neurosurg 2005;48(2):77-84.